Sugi Predict

Sugi Predict / Compounds / SCHEMBL56404

SCHEMBL56404

SCHEMBL56404

CC(C)(C)OC(=O)N1CCC(S(N)(=O)=O)CC1

nearest known ligand 0.61

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ HPGD P15428 1/20 0.53
▸ RECQL P46063 1/20 0.50
▸ EPHX1 P07099 1/20 0.50
▸ USP2 O75604 1/20 0.49
▸ SMN1; SMN2 Q16637 1/20 0.49
▸ GPR119 Q8TDV5 6/20 0.48
▸ CA12 O43570 1/20 0.47
▸ CA1 P00915 1/20 0.47
▸ CA2 P00918 1/20 0.47
▸ CA9 Q16790 1/20 0.47
▸ STS P08842 4/20 0.46
▸ KDM4E B2RXH2 1/20 0.46
▸ MAPT P10636 1/20 0.46
▸ THRB P10828 1/20 0.46
▸ PTPN2 P17706 1/20 0.46
▸ PTPN1 P18031 1/20 0.46
▸ PTPN6 P29350 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20635838 0.94 HPGD (0.55) HPGDRECQLEPHX1USP2SMN1; SMN2
SCHEMBL57472 0.90 HPGD (0.47) HPGDRECQLEPHX1USP2SMN1; SMN2
SCHEMBL20634422 0.85 NR1H2 (0.40) HPGDRECQLEPHX1USP2SMN1; SMN2
Methane SCHEMBL28121361 0.85 HPGD (0.54) HPGDRECQLEPHX1USP2SMN1; SMN2
SCHEMBL189924 0.85 RECQL (0.55) HPGDRECQLEPHX1USP2SMN1; SMN2
SCHEMBL56603 0.83 HPGD (0.53) HPGDRECQLEPHX1USP2SMN1; SMN2
SCHEMBL20599655 0.83 NR1H2 (0.49) HPGDRECQLEPHX1USP2SMN1; SMN2
SCHEMBL18669444 0.83 HPGD (0.50) HPGDRECQLGPR119CA12CA1
SCHEMBL1514778 0.82 EPHX1 (0.52) HPGDRECQLEPHX1USP2SMN1; SMN2
SCHEMBL32667629 0.82 HPGD (0.51) HPGDRECQLEPHX1USP2SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-118201908-A Azabiphenyls and uses thereof 正大天晴药业集团股份有限公司 2024-06-14 — — CN disclosed
WO-2024057013-A1 NLRP3 MODULATORS EXSCIENTIA AI LIMITED (GB) 2024-03-21 — — WO disclosed
US-11773058-B2 Sulfonamide carboxamide compounds INFLAZOME LIMITED (IE) 2023-10-03 — — US disclosed
WO-2023078463-A1 AZOBENZENE COMPOUND AND APPLICATION THEREOF 正大天晴药业集团股份有限公司 2023-05-11 — — WO disclosed
US-11634390-B2 Agricultural chemicals GLOBACHEM NV (BE) 2023-04-25 — — US disclosed
US-11634390-B2 Agricultural chemicals GLOBACHEM NV (BE) 2023-04-25 — — US disclosed
US-20230037255-A1 NOVEL SULFONAMIDE CARBOXAMIDE COMPOUNDS INFLAZOME LTD (IE) 2023-02-02 — — US disclosed
EP-3353176-B1 BICYCLIC COMPOUNDS AS ATX INHIBITORS HOFFMANN LA ROCHE (CH) 2022-01-19 — — EP disclosed
EP-3661925-B1 NOVEL SULFONAMIDE CARBOXAMIDE COMPOUNDS INFLAZOME LTD (IE) 2021-11-24 — — EP disclosed
CN-107922412-B Bicyclic compounds as ATX inhibitors 豪夫迈·罗氏有限公司 2021-02-23 — — CN disclosed
US-20140155375-A1 NOVEL COMPOUNDS GlaxoSmithKline Interllectual Property Limited (GB) 2014-06-05 — — US disclosed
EP-2717694-A1 NOVEL COMPOUNDS GlaxoSmithKline Intellectual Property Limited (GB) 2014-04-16 — — EP disclosed
WO-2014047427-A2 SUBSTITUTED BENZOFURAN, BENZOTHIOPHENE AND INDOLE MCL-1 INHIBITORS VANDERBILT UNIVERSITY (US) 2014-03-27 — — WO disclosed
WO-2012170752-A1 NOVEL COMPOUNDS GLAXO WELLCOME MANUFACTURING PTE LTD (SG) 2012-12-13 — — WO disclosed
US-8129546-B2 Derivatives for modulation of ion channels VERTEX PHARMACEUTICALS INCORPORATED (US) 2012-03-06 — — US disclosed
US-20110077269-A1 DERIVATIVES FOR MODULATION OF ION CHANNELS VERTEX PHARMACEUTICALS INCORPORATED (US) 2011-03-31 — — US disclosed
US-7842819-B2 Derivatives for modulation of ion channels VERTEX PHARMACEUTICALS INCORPORATED (US) 2010-11-30 — — US disclosed
EP-1948597-A1 DERIVATIVES FOR MODULATION OF ION CHANNELS Vertex Pharmaceuticals Incorporated (US) 2008-07-30 — — EP disclosed
US-20070203122-A1 Derivatives for modulation of ion channels VERTEX PHARMACEUTICALS INCORPORATED 2007-08-30 — — US disclosed
WO-2007050522-A1 DERIVATIVES FOR MODULATION OF ION CHANNELS VERTEX PHARMACEUTICALS INCORPORATED (US) 2007-05-03 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070203122-A1 Derivatives for modulation of ion channels TRPV1, TRPA1, TRPV2 HPGD 1667/4885RECQL 4079/4885EPHX1 2702/4885
US-11773058-B2 Sulfonamide carboxamide compounds NLRP3, NOD1, NLRP1 HPGD 3440/4885RECQL 930/4885EPHX1 2720/4885
US-20140155375-A1 NOVEL COMPOUNDS CYBB, NOX1, NOX4 HPGD 64/4885RECQL 3943/4885EPHX1 265/4885
US-20230037255-A1 NOVEL SULFONAMIDE CARBOXAMIDE COMPOUNDS NLRP3, NOD1, NLRP1 HPGD 2568/4885RECQL 431/4885EPHX1 1762/4885
US-20110077269-A1 DERIVATIVES FOR MODULATION OF ION CHANNELS TRPV1, TRPA1, TRPV2 HPGD 1667/4885RECQL 4079/4885EPHX1 2702/4885
US-11634390-B2 Agricultural chemicals DDT, DHFR, AS3MT HPGD 935/4885RECQL 1438/4885EPHX1 152/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.